Nektar Therapeutics (NASDAQ: NKTR) stock closed at $16.18 on 10/8/19 after a major decline of -13.3%. Moreover, this decline was accompanied by above average trading volume at 127% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -11.2% during the last week.
Current PriceTarget Research Rating
NKTR is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Nektar Therapeutics has a poor Appreciation Score of 22 and a very low Power Rating of 12, and the Lowest Value Trend Rating results.
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.